natgillin/translations-raw huggingface dataset:
feeding the crude 1,1,1,2,3-pentachloropropane into a reaction zone, to transform the crude 1,1,1,2,3-pentachloropropane into 1,1,2,3-tetrachloropropene and hydrogen chloride by dehydrochlorination, wherein the 1,1,2,3-tetrachloropropene and hydrogen chloride are removed from the reaction zone during the course of the dehydrochlorination reaction; and 
Postupak prema zahtjevu 1, gdje se postupak dehidrokloriranja provodi uporabom reaktivne destilacijske opreme koja obuhvaća reakcijsku zonu, zonu odvajanja 1 zonu kondenzacije, gdje se 1,1,2,3-tetrakloropropen i klorovodik uklanjanju iz reakcijske zone za dehidrokloriranje putem zone odvajanja i zone kondenzacije.
The solids were collected and dried in a vacuum oven at 40° C. to give Formula 43. 
Krutine su bile ohlađene i osušene u vakuumskoj pećnici kod 40%C da bi se dobila formula 43.
A method of treating a patient for an autoimmune ocular inflammatory disease (ACID), comprising administering to the patient an IL-23 antagonist. 
1L-23 antagonist, naznačen time, da se koristi u liječenju pacijenta s autoimunom očnom upalnom bolesti (AQID).
The method of claim 1, further comprising repeating the removal step at least once. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se sastoji u ponavljanju koraka uklanjanja najmanje jednom.
A pharmaceutical composition according to aspect 36, wherein said at least two different Ig-like molecules have been produced by recombinant host cells according to aspects 34 or 35. Aspect 38. A method for making a host cell for production of at least two different Ig-like molecules, the method comprising the step of introducing into said host cell nucleic acid sequences encoding at least a first, a second, a third and a fourth CH3-domain comprising polypeptide chain, wherein at least two of said nucleic acid sequences are provided with means for preferential pairing of said first and second CH3-domain comprising polypeptides and said third and fourth CH3-domain comprising polypeptides, wherein said nucleic acid sequences are introduced consecutively or concomitantly. 
Postupak za pripremu stanice domaćina za proizvodnju najmanje dva različita antitijela, pri čemu postupak sadrži korak uvođenja u navedenu stanicu domaćina sekvenci nukleinske kiseline koje kodiraju najmanje prvi, drugi, treći i četvrti polipeptidni lanac koji sadrži CH3 domenu, pri čemu navedeni prvi polipeptidni lanac koji sadrži CH3 domenu sadrži CH3 domenu humanog IgG koji sadrži lizinski (K) ostatak na aminokiselinskom položaju 366 u skladu s EU sustavom numeracije i pri čemu navedeni drugi polipeptidni lanac koji sadrži CH3 domenu sadrži CH3 domenu humanog IgG koji sadrži ostatak asparaginske kiseline (D) na aminokiselinskom položaju 351 u skladu s EU sustavom numeracije, pri čemu navedene sekvence nukleinske kiseline su uvedene uzastopno ili istovremeno.
The method of claim 1, wherein said autoimmune disease is a skin disorder, multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, type I diabetes, lupus, inflammatory bowel disease, Crohn's disease, myasthenia gravis, immunoglobulin nephropathies, myocarditis, autoimmune thyroid disorder, ulcerative colitis, chronic obstructive pulmonary disease, pemphigus vulgaris, or bullous pemphigoid. 
Spoj ili sol za upotrebu prema zahtjevu 22, naznačen time da navedena autoimuna bolest predstavlja poremećaj na koži, multiplu sklerozu, reumatoidni artritis, psorijazni artritis, juvenilni artritis, dijabetes tip I, lupus, upalnu bolest crijeva, Crohnovu bolest, mijasteniju gravis, imunoglobulinsku nefropatiju, miokarditis, ili autoimuni poremećaj štitnjače; ili
Criteria for an Acceptable Assay 
I. Kriteriji za prihvatljivi test
with R' and R", which may be identical or different each other, represented by hydrogen and an alkyl group having from 1 to 5 carbon atoms, 
s R' i R'', koje mogu biti međusobno identične ili različite, a predstavljene su vodikom i alkil-skupinom koja ima od jednoga do pet atoma ugljika;
at least one mobile suction means, which moves through the bottom of said at least one containing means suctioning the water flow containing the settled particles; 
najmanje jedno mobilno sredstvo za usisavanje (5), koje je konfigurirano za pomicanje duž dna (17) navedenog najmanje jednog sredstva za spremanje (8) usisavajući protok vode koji sadrži nataložene čestice;
as original therapy in all conditions, in which rapid reorganisation of blood circulation is mandatory; 
- kao izvorna terapija u svim stanjima u kojima je potrebna brza reorganizacija krvne opskrbe;
In this example, the process comprises: ● separation of the radium (224Ra and 228Ra) present in a natural thorium salt from the other radioelements that are present therewith, by n coprecipitations with barium sulphate that are carried out in succession in the same reactor, each coprecipitation comprising the preparation of an aqueous solution of the thorium salt, the in situ formation of barium-radium sulphate, followed by flocculation of this coprecipitate and its separation from the supernatant; 
Postupak za proizvodnju torija 228 iz prirodnih torijevih soli, naznačen time, da se obuhvaća redom sljedeće faze: a) odvajanja radija "Ra i ""Ra od drugih radioelementa prisutnih u ovoj soli, uz primjenu barem jedne koprecipitacije ovog radija sa barijevim sulfatom, a koprecipitacija podrazumijeva: i) dodavanje sumporne kiseline 1 barijeve soli u vodenu otopinu navedene prirodne torijeve soli kako bi se dobio koprecipitat barij-radij sulfata 1
g/L polyethylene glycol (PEG) having an average molecular weight of 2500 to 4500; 
(a) 525 g/l polietilen-glikola (PEG) prosječne molekulske težine od 2500 do 4500;
The compounds of claim 1 wherein R3 is a substituent selected from the group consisting of methyl and phenyl; wherein phenyl is optionally substituted with one to two substituents independently selected from the group consisting of chloro and carboxy. 
Spoj prema zahtjevu 1 naznačen time da R* je supstituent izabran iz skupine koju čine metil i fenil; pri čemu fenil je proizvoljno supstituiran sa jednim do dva supstituenta nezavisno izabrana iz skupine koju čine kloro i karboksi.
In specific embodiments, Tris base is added to a concentration of 5-50 mM, 7.5-100 Mm, 10-150 mM, 50-200 mM, 75-175 mM, 100-150 mM, 75-125 mM, or of any range whose upper and lower limits are selected from any of the foregoing values. 
(b) uvjeti aktivacije obuhvaćaju dodavanje katalitičke količine elastaze u otopinu koji sadrži autoaktivacijski protein proelastazu; i/ili (c) autoaktivacija se izvodi u prisustvu Tris baze u koncentraciji od 50-200 mM, 75-175 mM, 100-150 mM, 75-125 mM; i/ili
The capsule according to claim 4, wherein the upper face of the third annular portion includes a plurality of radial indentations thereon. 
Kapsula u skladu s patentnim zahtjevom 4, naznačena time, da se veći broj radijalnih udubljenja (21) nalazi na gornjoj strani trećeg dijela (15).
The process according to claim 1, wherein step (b) is performed by reacting B with methanesulfonyl chloride, in presence of triethylamine as base, in a mixture of MTBE and toluene in 3:2 volume ratio, at a temperature from about 5°C to about 10°C. 
Postupak prema zahtjevu 1, gdje se korak (b) provodi reagiranjem B s metansulfonil kloridom, u prisutnosti trietilamina kao baze, u smjesi MTBE i toluena u omjeru 3:2, pri temperaturi 5*C€ do 10*C.
during a steady state mode, directing a majority of the dewatered sludge through the heat exchanger and then to the hydrolysis reactor. 
(ii) tijekom stalnog načina rada, usmjeravanjem većine odvodnjenog mulja kroz izmjenjivač topline (216) 1 dalje u reaktor za hidrolizu (214).
The antibody or antigen-binding fragment thereof of claim 1, wherein the heavy chain comprises a heavy chain variable region of SEQ ID NO: 10, and the light chain comprises a light chain variable region of SEQ ID NO: 12. 
Antitijelo ili antigen vezujući fragment istog prema zahljevu 1, naznačen time da se teški lanac sastoji od varijabilne regije teškog lanca čiji je slijed SEQ ID NO: 10, a laki lanac se sastoji od varijabilne regije lakog lanca čiji je slijed SEQ ID NO: 12.
A pharmaceutical combination of Claim 25 wherein the hypolipidemic agent is an ileal Na+/bile acid cotransporter inhibitor. 
Farmaceutski sastav Zahtjeva 25, naznačen time, da je hipolipidemijsko sredstvo inhibitor ilealnog Na'/žučna kiselina kotransporta.
The following chromatographic separations are widely used: gel filtration (GF), ion exchange (IEX), hydrophobic interaction (HI) chromatography, affinity chromatography and HPLC (high-performance liquid chromatography). 
Raširene su slijedeće tehnike kromatografskog razdvajanja: gel-filtracija (GF), ionska izmjena (IEX), kromatografija hidrofobnih interakcija, afinitetna kromatografija i HPLC (tekućinska kromatografija visoke učinkovitosti).
c = 33.075 (4) Å Y = 90°, and/or wherein Form I is characterized by one or more peaks at 15.4 degrees, 16.3 degrees, and 14.5 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation at 40 kV, 35 mA. 
a = 4.9626 (7) Å a = 90° b = 12.2994 (18) Å B = 93.938 (9)° c = 33.075 (4) Å Y = 90°, i/ili gdje je oblik I karakteriziran s jednim ili više vrhova na 15.4 stupnjeva ± 0.2 stupnja, 16.3 stupnjeva ± 0.2 stupnja, i 14.5 stupnjeva ± 0.2 stupnja u difrakciji redgneskih zraka na prahu dobivenih pomoću Cu K alfa zračenja na 40 kV, 35 mA.
or their pharmaceutically acceptable salts, hydrates, or hydrated salts, or the polymorphic crystalline structures of these compounds or their optical isomers, racemates, diastereomers or enantiomers. 
kao i odgovarajući N-hidroksisukcinimidilni esteri, ili njihove farmaceutski prihvatljive soli, hidrati, ili hidratirane soli, ili polimorfne kristalne strukture tih spojeva ili njihovih optičkih izomera, racemata, dijastereomeri ili enantiomeri.
Cell of any of the claims 10 to 12 characterized in that the shape of the container has one of the following forms: ball, cubical, rhombic, polyhedral, flat concave, convex, biconvex, biconcave plane, with micro lenses of a side exposed to the light to concentrate it and plane, cylindrical, cylindrical across circular, hollow cylinder, circular cone (straight), truncated cone, rectangular prism (straight), oblique prism, rectangular pyramid (straight), truncated pyramid, truncated spherical segment, spherical segment, spherical, spherical sector with cylindrical perforation, sphere with conical perforations, bull (circular ring of section), cylinder with inclined cut, cylindrical wedge, barrel, isolated prismatoid. 
Stanica prema bilo kojem od zahtjeva 10 do 12, naznačena time, da spremnik ima jedan od oblika kako slijedi: lopta, kubični oblik, romboid, polihedralni oblik, ravno-konkavni oblik, konveksni oblik, bikonveksni oblik, bikonkavna ravnina, oblik s mikrolećama sa strane, koje su izložene svjetlosti da je koncentriraju 1 izglade, cilindar, cilindar ukršten krugom, šuplji cilindar, kružni stožac (ravan), krnji stožac, pravokutna prizma (ravna), nakrivljena prizma, pravokutna piramida (ravna), krnja piramida, krnji obli segment, obli segment, kuglasti oblik, oblo područje s cilindričnom perforacijom, kugla s koničnom perforacijom, bikovo oko (dio kružnog prstena), cilindar s kosim odrezanim dijelom, cilindrični odsječak, bačva, izolirani prizmatold.
In a specific embodiment, the novel method allows the preparation of compounds according to formula (I), wherein R is C1-C6 -alkyl (e.g. 
U specifičnoj izvedbi, novi postupak omogućuje pripravu spojeva u skladu s formulom (I), od čega je R C,-Cg-alkil (pr.
The method according to Paragraph 37, in which the treatment elicits a partial response. The method according to Paragraph 37, in which the treatment elicits a minimal response. Use of HuLu63 in the preparation of a first medicament, and the use of bortezimob in the preparation of a second medicament, said medicaments for use in the treatment of multiple myeloma of a human patient, wherein the HuLuc63 is administered as an intravenous infusion at a dosage from 2.5 mg/kg to 20 mg/kg and wherein the bortezimob is administered as an intravenous infusion at a dosage from 0.2 mg/m2 to 2.0 mg/m2. 
Upotreba HuLuc63 u pripravi lijeka, spomenuti HuLuc63 kao humanizirano antitijelo IgG1 ima varijabilno područje teškog lanca koje odgovara sekvenci SEQ ID NO;:5 1 varijabilno područje lakog lanca koje odgovara sekvenci SEQ ID NO:6; za liječenje multiplog mijeloma ljudskog pacijenta, gdje se HuLuc63 primijenjuje u kombinaciji s bortezomibom i gdje se HuLuc63 daje kao intravenozna infuzija u dozi od 2.5 mg/kg do20 mg/kg, a bortezomib se treba primijeniti kao intravenozna infuzija u dozi od 0.2 mg/m2 do 2.0 mg/m2.
A process for the preparation of a compound according to claim 1 or a salt thereof, which process comprises reacting of a compound of formula (VIII) Wherein R1, R2, R4, A, B and Q are as defined above and L3 represents a leaving group and a compound of formula M1-Y-R3 wherein R3 and Y are as defined in claim 1 and M1 represents hydrogen or a metal residue optionally in the presence of a suitable and optionally using a suitable transition metal catalyst system and thereafter optionally carrying out one or more of the following reactions: 
R (VIII) ukojem R',R', R',A, B i Q su kao što je definirano iznad i L* predstavlja odlazeću skupinu, i spoja formule M'-Y5 R* u kojem Rž i Y su kao što je definirano u zahtjevu 1 i M! predstavlja vodik ili metalni ostatak, po potrebi u prisutnosti odgovarajućeg i po potrebi upotrebom prikladnog katalizatorskog sustava s prijelaznim metalom i nakon toga po potrebi izvođenje jedne ili više od sljedećih reakcija: a.
A pharmaceutical composition comprising a therapeutically-effective amount of a single immunoglobulin variable domain antibody of any of claims 1-11 and a pharmaceutically acceptable carrier. 
Farmaceutska smjesa, naznačena time, što uključuje terapijski efikasnu količinu antitijela koje sadrži jednu imunoglobulinsku varijabilnu domenu iz bilo kojeg od zahtjeva 1 do 6 ili dvojno specifični ligand prema zahtjevu 7 ili 8, i farmaceutski prihvatljivi nosač.
In the illustrated embodiment, the valve element 5 or the metered dose valve 2 is mounted by a metal cup 16 to the container 3 . 
U predloženoj izvedbi, element ventila 5 ili ventil za odmjeravanje doze 2 montiran je na spremnik 3 pomoću metalne kapice 16.
The composition or vaccine of any one of claims 1-8 for use in a method for inducing an immunogenic or protective response in an animal against one or more avian pathogens, said method comprising at least one administration of the composition or vector. The composition or vaccine for use according to claim 10, wherein the method is a prime-boost administration regimen. 
Pripravak ili cjepivo prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen/o time, da se upotrebljava u postupku induciranja zaštitne reakcije kod životinje, protiv NDV i opcionalno, protiv jednog ili više daljnjih ptičjih patogena, pri čemu taj postupak obuhvaća najmanje jednu primjenu pripravka ili cjepiva.
The process of claim 1, wherein the fourth organic solvent is an aprotic solvent. 
Postupak prema patentnom zahtjevu 2, pri čemu je organsko otapalo korišteno u koraku ic, neprotonsko otapalo.
In one embodiment there is provided a hydrogel according to the invention wherein the thickener is acrylate/C10-30 alkyl acrylate crosspolymer. Acrylates/C10-30 alkyl acrylate crosspolymer is a cross-linked polyacrylic acid. In one embodiment there is provided a hydrogel consisting essentially of 91.15% purified water, 5% Lactokine™, 1% glycerine, 0.8% trolamine, 0.75% phenoxyethanol and ethylhexylglycerine, 0.4% carbomer 940, 0.3% carbomer TR1, 0.5% acrylate/C10-30 alkyl acrylate crosspolymer, and 0.1% edetate disodium. 
Hidrogel prema zahtjevu 1, koji esencijalno obuhvaća: 91,15% w/w pročišćene vode, 5% w/w laktokina, 1% w/w glicerina, 0,8% w/w trolamina, 0,75% w/w fenoksietalnola i etilheksilglicerina, 0,4% w/w karbomera 940, 0,3% w/w karbomera TRI, 0,5% w/w akrilata/C,9.29 alkil akrilat križni polimer, i 0,1% w/w dinatrijevog edetata i naznačen time da je viskoznost u rasponu od 290,000 do 510,000 cP.
A hydraulically and chemically bonding refractory magnesia cement, which comprises a caustic magnesia component having a BET specific surface area of at least 0.5 m2/g, and a carboxylic acid component, characterized in that the carboxylic acid component consists of at least one carboxylic acid that is only slightly water soluble and/or has a low dissolution rate in aqueous solutions, and which carboxylic acid component is capable of generating at least one soluble magnesium salt upon contact of said cement with water. 
HR P20191134 T1 PATENTNI ZAHTJEVI Hidraulički i kemijski vezujući refraktorni magnezijski cement, koji sadrži kaustični sastojak magnezije koji ima BET specifičnu površinu od barem 0,5 m'/g, i sastojak karboksilne kiseline, naznačen time što se sastojak brzinu otapanja u vodenim otopinama što znači da ima topljivost na 20C od 0,5 do 50 g/L, ili brzinu otapanja u vodenoj otopini na 20?C€ od 1 do 50 g/L/h.
The roll of any of the preceding claims, wherein the Mo content in the steel composition is between 1.45 - 1.55 % Mo in terms of % per weight of total roll weight. 
Valjak prema prethodnim zahtjevima, pri čemu sadržaj Mo u sastavu čelika iznosi između 1,45-1,55 % Mo u postotnoj težini ukupne težine valjka.
The mouse of claim 1, wherein the λ light chain allele comprises a contiguous sequence of the human λ light chain locus that spans from Vλ3-27 to Vλ3-1 and a contiguous sequence of the human λ light chain locus that spans from Vλ5-52 to Vλ1-40. 
graničnu sekvenciju humanog lokusa lakog λ lanca koja se proteže od hVλ3-27 do hVλ3-1; ili graničnu sekvenciju humanog lokusa lakog λ lanca koja se proteže od hVλ5-52 do hVλ1-40 i graničnu sekvenciju humanog lokusa lakog λ lanca koja se proteže od hVλ3-29 do hVλ3-1.
Adjust the final batch weight to 1190.0 kg using water, purified. 
HR P20080289 T3 krajnju masu gmpe do 1190.0 kg primjenom vode, pročišćene.
active ingredient, 
-90 % aktivnog sastojka
The method of any one of Claims 1 to 23, further comprising cooling the soluble spray-dried composition from a heated temperature below the glass transition temperature. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 23, koji se dodatno sastoji u hlađenju topivog pripravka osušenog raspršivanjem nakon grijanja na temperaturu ispod staklišta.
Hose as claimed in claims 3 and 5, wherein said braided fabric layer (4) is in contact with said sixth anti-algae layer (3). 
Crijevo prema zahtjevima 3 1 5, gdje je taj pleteni sloj (4) u doticaju sa šestim slojem protiv alga (3).
Figure 4 shows a side view of a mouthpiece cap which can be incorporated into an inhaler according to a preferred form of the present invention, the cap is shown from the side and the cap is in the closed position in which it fits over the mouthpiece in order to occlude it; and 
je bočni pogled na zatvarač kljuna koji se može ugraditi u inhalator sukladno poželjnoj realizaciji ovog izuma, a zatvarač je prikazan bočno i u zatvorenom je položaju u kojem je postavljen preko kljuna i potpuno ga okružuje; te
Ar is selected from the group consisting of phenyl and thiophen-yl; 
Ar je odabran iz skupine koju čine:
Preferably, R1 is represented by any of the following structures: 
Spoj uz skladu s patentnim zahtjevom 1, naznačen time što R' prikazuje bilo koja od sljedećih struktura: o
Chronic Lymphocyte Leukemia. 
limfocitna leukemija.
A compound of formula I, which is (S)-4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonic acid salt or a solvate thereof 
Spoj formule I, naznačen time što je sol (S)-4-[(3-fuorfenoksi)fenilmetillpiperidina s metansulfonskom kiselinom ili njezin solvat.
An oral pharmaceutical tablet according to claim 8, wherein the filler is present in an amount from 0.5% to 10%, preferably from 0.5% to 8%, and more preferably from 1% to 5% by weight of the total weight of the tablet. 
Oralna farmaceutska tableta u skladu s patentnim zahtjevom 8, naznačena time što punilo čini, količinski, od 0,5% do 10%, po mogućnosti od 0,5% do 8%, a poželjnije od 1% do 5%, težinski, od ukupne težine tablete.
The process of claim 14 wherein the solution is added to water at a temperature of 10 °C to 30 °C. 
Proces prema zahtjevu 14, naznačen time da se otopina dodaje u vodu pri temperaturi od 10 C do 30 C.
In another aspect, the present invention provides a method of producing a targeted therapeutic fusion protein including a step of culturing mammalian cells in a cell culture medium, wherein the mammalian cells carry the nucleic acid of the invention, in particular, as described in various embodiments herein; and the culturing is performed under conditions that permit expression of the targeted therapeutic fusion protein. 
Postupak za proizvodnju ciljanog terapeutskog fuzijskog proteina naznačen time da sadrži korak: kultiviranja stanica sisavaca u mediju stanične kulture, pri čemu stanice sisavaca nose nukleinsku kiselinu prema zahtjevu 14; i kultiviranje se provodi pod uvjetima koji omogućuju ekspresiju ciljanog terapeutskog fuzijskog proteina.
A pharmaceutical composition comprising a tumour associated peptide according to any one of Claims 1 to 6, a nucleic acid according to Claim 7 or 8 or an expression vector according to Claim 9, and a pharmaceutically acceptable carrier. 
Farmaceutski sastav koji obuhvaća tumoru pridruženi peptid prema bilo kojem od Zahtjeva 1 do 3, nukleinsku kiselinu prema Zahtjevu 4 ili 5 ili vektor ekspresije prema Zahtjevu 6 te farmaceutski prikladan nosač, poželjno u obliku cjepiva protiv raka, a po izboru može sadržavati barem jedan prikladan adjuvans.
modify or otherwise at least one of the data of the current partition as a function of the result of the comparison, and in that it comprises means for coding the at least one modified data item, in the case of modification by the processing means. 
- < izmjenu ili ne barem jednog podatka trenutne particije u funkciji rezultata usporedbe, te time da sadrži sredstva (CE CO) za kodiranje podataka obuhvaćene particije koja sadrži barem jedan izmijenjeni podatak bez predznaka barem jednog izmijenjenog podatka, u slučaju izmjene pomoću navedenih sredstava za obradu.
The polypeptide or composition for use according to claim 20, wherein the subject has Duchenne's muscular dystrophy. 
Polipeptid ili pripravak namijenjeni upotrebi u skladu s patentnim zahtjevom 20, naznačeni time što subjekt ima Duchenneovu mišićnu distrofiju.
A compound according to claim 1 having the structure or a pharmaceutically acceptable salt or solvate thereof. 
Spoj u skladu s patentnim zahtjevom 1, sa strukturom vro ili njegova farmaceutski prihvatljiva sol ili solvat.
Use of the compound according to claim 1 or a salt thereof, for the manufacture of a pharmaceutical composition for preventing or treating a disease associated with 17BHSD type 5. 
Uporaba spoja prema zahtjevu 1 ili njegove soli, naznačena time, da je za proizvodnju farmaceutskog sastava za prevenciju ili liječenje bolesti povezane s 17BHSD tip 5.
The compound for use as claimed in claim 19, wherein said treatment comprises administering to the subject a therapeutically effective amount of (a) at least one compound of claim 1; and (b) at least one additional agent selected from an ERR-a inverse agonist, a second ERR-a antagonist, a glucokinase modulator, an anti-diabetic agent, an anti-obesity agent, a lipid lowering agent, an anti-thrombotic agent, direct thrombin inhibitor, and a blood pressure lowering agent, said administration being in any order. 
Spoj za uporabu kako je zatraženo u zahtjevu 19, naznačen time da se navedeno liječenje sastoji od davanja subjektu terapeutski učinkovite količine (a) barem jednog spoja prema zahtjevu 1; i (b) barem jednog dodatnog sredstva odabranog od ERR-qa inverznog agonista, drugog ERR-a antagonista, modulatora glukokinaze, anti-dijabetskog sredstva, sredstva protiv pretilosti, sredstva za snižavanje lipida, sredstva protiv tromboze, direktnog inhibitora trombina, te sredstva za snižavanje krvnog tlaka, a navedeno davanje je u bilo kojem redoslijedu.